Diagnostic Accuracy of Antibody-based Rapid Diagnostic Tests in Detecting Coronavirus Disease 2019: Systematic Review

Overview

Journal Arch Med Sci

Specialty General Medicine

Date 2022 Jul 14

PMID 35832707

Authors

Tiara Josephine Gracienta

Ryan Herardi

Frans Santosa

Taufiq Fredrik Pasiak

Yanto Sandy Tjang

Affiliations

Soon will be listed here.

Abstract

Introduction: The rapid transmission of coronavirus disease 2019 (COVID-19) requires a fast, accurate, and affordable detection method. Despite doubts of their diagnostic accuracy, rapid diagnostic tests (RDTs) are used worldwide due to their practicality. This systematic review aims to determine the diagnostic accuracy of antibody-based RDTs in detecting COVID-19.

Material And Methods: A literature search was carried out on five journal databases using the PRISMA-P 2015 method. We included all studies published up to February 2021. The risk of bias was evaluated using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Diagnostic Test Accuracy Studies. Data regarding peer-review status, study design, test kit information, immunoglobulin class, target antigen, and the number of samples were extracted and tabulated. We estimated the pooled sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) with a 95% confidence interval.

Results: Thirty-three studies met the eligibility criteria. The pooled data results showed that the combined detection method of IgM or IgG had the highest sensitivity and NPV, which were 73.41% (95% CI: 72.22-74.57) and 75.34% (95% CI: 74.51-76.16), respectively. The single IgG detection method had the highest specificity and PPV of 96.68% (95% CI: 96.25-97.07) and 95.97% (95% CI: 95.47-96.42%), respectively.

Conclusions: Antibody-based RDTs are not satisfactory as primary diagnostic tests but have utility as a screening tool.

Citing Articles

Rapid assays of SARS-CoV-2 virus and noble biosensors by nanomaterials.

Liu Y, Li Y, Hang Y, Wang L, Wang J, Bao N Nano Converg. 2024; 11(1):2.

PMID: 38190075 PMC: 10774473. DOI: 10.1186/s40580-023-00408-z.

An update on lateral flow immunoassay for the rapid detection of SARS-CoV-2 antibodies.

Spicuzza L, Campagna D, Di Maria C, Sciacca E, Mancuso S, Vancheri C AIMS Microbiol. 2023; 9(2):375-401.

PMID: 37091823 PMC: 10113162. DOI: 10.3934/microbiol.2023020.

Antibody tests for identification of current and past infection with SARS-CoV-2.

Fox T, Geppert J, Dinnes J, Scandrett K, Bigio J, Sulis G Cochrane Database Syst Rev. 2022; 11():CD013652.

PMID: 36394900 PMC: 9671206. DOI: 10.1002/14651858.CD013652.pub2.

References

Serre-Miranda C, Nobrega C, Roque S, Canto-Gomes J, Silva C, Vieira N . Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalised COVID-19 patients. Int J Infect Dis. 2021; 104:661-669. PMC: 7817432. DOI: 10.1016/j.ijid.2021.01.038. View

Nicol T, Lefeuvre C, Serri O, Pivert A, Joubaud F, Dubee V . Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech). J Clin Virol. 2020; 129:104511. PMC: 7295485. DOI: 10.1016/j.jcv.2020.104511. View

Candel F, Vinuela-Prieto J, Gonzalez Del Castillo J, Barreiro Garcia P, Fragiel Saavedra M, Hernandez Piriz A . Utility of lateral flow tests in SARS-CoV-2 infection monitorization. Rev Esp Quimioter. 2020; 33(4):258-266. PMC: 7374028. DOI: 10.37201/req/052.2020. View

de Almeida S, Spalanzani R, Nogueira M, Sanada B, Cavalli B, Rotta I . Rapid Serological Tests for SARS-CoV-2: Diagnostic Performance of 4 Commercial Assays. Med Princ Pract. 2021; 30(4):385-394. PMC: 8339017. DOI: 10.1159/000516776. View

Adams E, Ainsworth M, Anand R, Andersson M, Auckland K, Baillie J . Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel. Wellcome Open Res. 2021; 5:139. PMC: 7941096. DOI: 10.12688/wellcomeopenres.15927.1. View

Dortet L, Ronat J, Vauloup-Fellous C, Langendorf C, Mendels D, Emeraud C . Evaluating 10 Commercially Available SARS-CoV-2 Rapid Serological Tests by Use of the STARD (Standards for Reporting of Diagnostic Accuracy Studies) Method. J Clin Microbiol. 2020; 59(2). PMC: 8111137. DOI: 10.1128/JCM.02342-20. View

Delliere S, Salmona M, Minier M, Gabassi A, Alanio A, Le Goff J . Evaluation of the COVID-19 IgG/IgM Rapid Test from Orient Gene Biotech. J Clin Microbiol. 2020; 58(8). PMC: 7383543. DOI: 10.1128/JCM.01233-20. View

Lou B, Li T, Zheng S, Su Y, Li Z, Liu W . Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset. Eur Respir J. 2020; 56(2). PMC: 7401320. DOI: 10.1183/13993003.00763-2020. View

Chan C, Shahul S, Coleman C, Tesic V, Parker K, Yeo K . Evaluation of the Truvian Easy Check COVID-19 IgM/IgG Lateral Flow Device for Rapid Anti-SARS-CoV-2 Antibody Detection. Am J Clin Pathol. 2020; 155(2):286-295. PMC: 7665287. DOI: 10.1093/ajcp/aqaa221. View

10.

Lee H, Lee B, Seok S, Baek M, Lee H, Kim D . Production of specific antibodies against SARS-coronavirus nucleocapsid protein without cross reactivity with human coronaviruses 229E and OC43. J Vet Sci. 2010; 11(2):165-7. PMC: 2873818. DOI: 10.4142/jvs.2010.11.2.165. View

11.

Andrey D, Cohen P, Meyer B, Torriani G, Yerly S, Mazza L . Head-to-Head Accuracy Comparison of Three Commercial COVID-19 IgM/IgG Serology Rapid Tests. J Clin Med. 2020; 9(8). PMC: 7463984. DOI: 10.3390/jcm9082369. View

12.

Montesinos I, Gruson D, Kabamba B, Dahma H, van den Wijngaert S, Reza S . Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies. J Clin Virol. 2020; 128:104413. PMC: 7198434. DOI: 10.1016/j.jcv.2020.104413. View

13.

Pallett S, Rayment M, Patel A, Fitzgerald-Smith S, Denny S, Charani E . Point-of-care serological assays for delayed SARS-CoV-2 case identification among health-care workers in the UK: a prospective multicentre cohort study. Lancet Respir Med. 2020; 8(9):885-894. PMC: 7380925. DOI: 10.1016/S2213-2600(20)30315-5. View

14.

Wu J, Tseng W, Lin C, Lee T, Chung M, Huang C . Four point-of-care lateral flow immunoassays for diagnosis of COVID-19 and for assessing dynamics of antibody responses to SARS-CoV-2. J Infect. 2020; 81(3):435-442. PMC: 7295501. DOI: 10.1016/j.jinf.2020.06.023. View

15.

Shen B, Zheng Y, Zhang X, Zhang W, Wang D, Jin J . Clinical evaluation of a rapid colloidal gold immunochromatography assay for SARS-Cov-2 IgM/IgG. Am J Transl Res. 2020; 12(4):1348-1354. PMC: 7191168. View

16.

Whitman J, Hiatt J, Mowery C, Shy B, Yu R, Yamamoto T . Evaluation of SARS-CoV-2 serology assays reveals a range of test performance. Nat Biotechnol. 2020; 38(10):1174-1183. PMC: 7740072. DOI: 10.1038/s41587-020-0659-0. View

17.

Maya V, Embekkat Kaviyil J, Ponnambath D, Nair R, Bhatt A, Pilankatta R . Evaluation of diagnostic accuracy of developed rapid SARS-COV-2 IgG antibody test kit using novel diluent system. Virusdisease. 2021; 32(1):78-84. PMC: 7931782. DOI: 10.1007/s13337-021-00669-4. View

18.

Swadzba J, Bednarczyk M, Anyszek T, Martin E . A comparison of 7 commercial anti-SARS-CoV-2 antibody immunoassays. Arch Med Sci. 2023; 19(5):1281-1288. PMC: 10507786. DOI: 10.5114/aoms.2020.98361. View

19.

Jacofsky D, Jacofsky E, Jacofsky M . Understanding Antibody Testing for COVID-19. J Arthroplasty. 2020; 35(7S):S74-S81. PMC: 7184973. DOI: 10.1016/j.arth.2020.04.055. View

20.

Trevethan R . Sensitivity, Specificity, and Predictive Values: Foundations, Pliabilities, and Pitfalls in Research and Practice. Front Public Health. 2017; 5:307. PMC: 5701930. DOI: 10.3389/fpubh.2017.00307. View